Recombinant bovine basic fibroblast growth factor for the treatment of corticosteroid-dependent dermatitis: a randomized double-blind placebo-controlled trial
10.3760/cma.j.issn.0412-4030.2018.03.014
- VernacularTitle:外用重组牛碱性成纤维细胞生长因子治疗激素依赖性皮炎的随机、双盲、安慰剂对照观察
- Author:
Weixia WANG
1
;
Min LI
;
Li'na DENG
;
Huajuan WU
;
Ting WU
;
Yunfei LI
;
Xueli LI
Author Information
1. 河南省人民医院皮肤科
- Keywords:
Fibroblast growth factor 2;
Treatment outcome;
Drug toxicity;
Corticosteroid-dependent dermatitis;
Skin barrier
- From:
Chinese Journal of Dermatology
2018;51(3):217-220
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of recombinant bovine basic fibroblast growth factor in the treatment of corticosteroid-dependent dermatitis.Methods A randomized,double-blind,placebo-controlled clinical trial was carried out.By simple randomization,64 patients with corticosteroid-dependent dermatitis were randomly and equally divided into 2 groups:treatment group topically applying recombinant bovine basic fibroblast growth factor gel twice a day for 4 consecutive weeks,and control group topically applying the gel vehicle twice a day for 4 consecutive weeks.Clinical symptoms and signs were scored before the treatment and after 1-,2-and 4-week treatment.Meanwhile,the water content of the stratum corneum,skin sebum content and transepidermal water loss (TEWL) of the skin lesions were detected.Results Thirty-one patients in the treatment group and 30 in the control group completed the trial.The clinical symptom and sign scores in the treatment group were significantly lower at week 2 and 4 after starting treatment (1.35 ± 0.55 and 1.00 ± 0.45,respectively) than that before treatment (2.77 ± 0.43,both P ＜ 0.05),as well as lower at week 1 (2.06 ± 0.51),2 and 4 after starting treatment than that in the control group (2.43 ± 0.57,2.17 ± 0.53,1.93 ± 0.45,respectively,all P ＜ 0.05).The treatment group showed significantly increased water content of the stratum corneum at week 4 after starting treatment,significantly increased skin sebum content,but decreased TEWL at week 2 and 4 after starting treatment compared with those before treatment (all P ＜ 0.05).Compared with the control group,the treatment group showed significantly higher skin sebum content at week 2 and 4 after starting treatment,higher water content of the stratum corneum,but lower TEWL at week 4 after starting treatment (all P ＜ 0.05).No adverse reactions were observed in either of the 2 groups.Conclusion Recombinant bovine basic fibroblast growth factor is effective and safe for the treatment of corticosteroid-dependent dermatitis,and contributes to repairing and reconstructing the skin barrier function.
